Indicated for: nasal congestion; rhinitis
Substance: ipratropium bromide + salbutamol (antimuscarinic bronchodilator + beta-2 adrenergic agonist)
ATC: R03AL02 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids)
The combination of ipratropium bromide and salbutamol is used for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Ipratropium bromide works by blocking muscarinic receptors, while salbutamol stimulates beta-2 adrenergic receptors, relaxing airway muscles.
The medication is administered as an aerosol or nebulizer solution, as directed by a doctor. It is important to follow the recommended dose to achieve the best results.
Side effects may include dry mouth, cough, tremors, or palpitations. In rare cases, severe allergic reactions or breathing difficulties may occur.
This combination is not recommended for patients with hypersensitivity to any of the components or severe cardiac conditions.